Muhammad Musaab Munir, Mujtaba Khalil, Muhammad Muntazir Mehdi Khan, Selamawit Woldesenbet, Mary Dillhoff, Susan Tsai, Timothy M Pawlik
{"title":"复杂癌症手术后手术结果医院旗舰系统协会。","authors":"Muhammad Musaab Munir, Mujtaba Khalil, Muhammad Muntazir Mehdi Khan, Selamawit Woldesenbet, Mary Dillhoff, Susan Tsai, Timothy M Pawlik","doi":"10.6004/jnccn.2024.7096","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We evaluated variations in patient outcomes and financial expenditures following complex cancer surgery across flagship hospitals and their affiliates.</p><p><strong>Methods: </strong>Using Medicare 100% Standard Analytic Files (2018-2021), we identified patients undergoing resection of lung, esophageal, gastric, hepatopancreatobiliary, or colorectal cancer. Flagship hospitals were defined as the highest-volume major teaching hospital within a system in each region. Propensity score matching was performed to create a 1:1 matched cohort to assess the association between flagship systems, hospitals, affiliates, and outcomes.</p><p><strong>Results: </strong>Among 110,670 patients, 55,335 treated within a flagship hospital system (median age, 73 years [IQR, 69-79]; including 29,381 [53.1%] women) were matched with 55,335 patients who were not (median age, 73 years [IQR, 69-79]; including 29,274 [52.9%] women) across 35 regions. Patients at flagship system hospitals had lower 30-day mortality rates than matched controls (4.23% vs 4.88%; difference, -0.65% [95% CI, -0.89% to -0.40%]; P<.001). Mortality was also lower at flagship hospitals (2.76% vs 3.82%; difference, -1.06% [95% CI, -1.62% to -0.50%]) and flagship affiliates (4.46% vs 4.79%; difference, -0.32% [95% CI, -0.58 to -0.07]) compared with controls (both P<.001). However, patients who underwent cancer surgery at flagship hospital systems had higher expenditures ($21,011 vs $20,016; difference, +$995 [95% CI, $797 to $1,193]; P<.001).</p><p><strong>Conclusions: </strong>Flagship hospitals are the primary drivers of decreased postoperative mortality following complex oncologic surgical procedures performed within their systems, although expenditures were higher compared with unaffiliated hospitals.</p>","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":"23 5","pages":""},"PeriodicalIF":14.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association of Hospital Flagship System Affiliation on Surgical Outcomes Following Complex Cancer Surgery.\",\"authors\":\"Muhammad Musaab Munir, Mujtaba Khalil, Muhammad Muntazir Mehdi Khan, Selamawit Woldesenbet, Mary Dillhoff, Susan Tsai, Timothy M Pawlik\",\"doi\":\"10.6004/jnccn.2024.7096\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>We evaluated variations in patient outcomes and financial expenditures following complex cancer surgery across flagship hospitals and their affiliates.</p><p><strong>Methods: </strong>Using Medicare 100% Standard Analytic Files (2018-2021), we identified patients undergoing resection of lung, esophageal, gastric, hepatopancreatobiliary, or colorectal cancer. Flagship hospitals were defined as the highest-volume major teaching hospital within a system in each region. Propensity score matching was performed to create a 1:1 matched cohort to assess the association between flagship systems, hospitals, affiliates, and outcomes.</p><p><strong>Results: </strong>Among 110,670 patients, 55,335 treated within a flagship hospital system (median age, 73 years [IQR, 69-79]; including 29,381 [53.1%] women) were matched with 55,335 patients who were not (median age, 73 years [IQR, 69-79]; including 29,274 [52.9%] women) across 35 regions. Patients at flagship system hospitals had lower 30-day mortality rates than matched controls (4.23% vs 4.88%; difference, -0.65% [95% CI, -0.89% to -0.40%]; P<.001). Mortality was also lower at flagship hospitals (2.76% vs 3.82%; difference, -1.06% [95% CI, -1.62% to -0.50%]) and flagship affiliates (4.46% vs 4.79%; difference, -0.32% [95% CI, -0.58 to -0.07]) compared with controls (both P<.001). However, patients who underwent cancer surgery at flagship hospital systems had higher expenditures ($21,011 vs $20,016; difference, +$995 [95% CI, $797 to $1,193]; P<.001).</p><p><strong>Conclusions: </strong>Flagship hospitals are the primary drivers of decreased postoperative mortality following complex oncologic surgical procedures performed within their systems, although expenditures were higher compared with unaffiliated hospitals.</p>\",\"PeriodicalId\":17483,\"journal\":{\"name\":\"Journal of the National Comprehensive Cancer Network\",\"volume\":\"23 5\",\"pages\":\"\"},\"PeriodicalIF\":14.8000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the National Comprehensive Cancer Network\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.6004/jnccn.2024.7096\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Comprehensive Cancer Network","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6004/jnccn.2024.7096","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:我们评估了旗舰医院及其附属医院复杂癌症手术后患者预后和财务支出的差异。方法:使用医疗保险100%标准分析文件(2018-2021),我们确定了接受肺癌、食管癌、胃癌、肝胆癌或结直肠癌切除术的患者。旗舰医院被定义为每个地区系统内容量最高的主要教学医院。进行倾向评分匹配以创建1:1匹配的队列,以评估旗舰系统、医院、附属机构和结果之间的关联。结果:在110670例患者中,55335例在旗舰医院系统接受治疗(中位年龄73岁[IQR, 69-79];包括29381例(53.1%)女性)和55335例非女性患者(中位年龄73岁[IQR, 69-79];包括35个地区的29274名(52.9%)女性。旗舰系统医院的患者30天死亡率低于匹配对照组(4.23% vs 4.88%;差异为-0.65% [95% CI, -0.89%至-0.40%];结论:旗舰医院是在其系统内进行复杂肿瘤外科手术后死亡率降低的主要驱动因素,尽管与非附属医院相比,旗舰医院的支出更高。
Association of Hospital Flagship System Affiliation on Surgical Outcomes Following Complex Cancer Surgery.
Background: We evaluated variations in patient outcomes and financial expenditures following complex cancer surgery across flagship hospitals and their affiliates.
Methods: Using Medicare 100% Standard Analytic Files (2018-2021), we identified patients undergoing resection of lung, esophageal, gastric, hepatopancreatobiliary, or colorectal cancer. Flagship hospitals were defined as the highest-volume major teaching hospital within a system in each region. Propensity score matching was performed to create a 1:1 matched cohort to assess the association between flagship systems, hospitals, affiliates, and outcomes.
Results: Among 110,670 patients, 55,335 treated within a flagship hospital system (median age, 73 years [IQR, 69-79]; including 29,381 [53.1%] women) were matched with 55,335 patients who were not (median age, 73 years [IQR, 69-79]; including 29,274 [52.9%] women) across 35 regions. Patients at flagship system hospitals had lower 30-day mortality rates than matched controls (4.23% vs 4.88%; difference, -0.65% [95% CI, -0.89% to -0.40%]; P<.001). Mortality was also lower at flagship hospitals (2.76% vs 3.82%; difference, -1.06% [95% CI, -1.62% to -0.50%]) and flagship affiliates (4.46% vs 4.79%; difference, -0.32% [95% CI, -0.58 to -0.07]) compared with controls (both P<.001). However, patients who underwent cancer surgery at flagship hospital systems had higher expenditures ($21,011 vs $20,016; difference, +$995 [95% CI, $797 to $1,193]; P<.001).
Conclusions: Flagship hospitals are the primary drivers of decreased postoperative mortality following complex oncologic surgical procedures performed within their systems, although expenditures were higher compared with unaffiliated hospitals.
期刊介绍:
JNCCN—Journal of the National Comprehensive Cancer Network is a peer-reviewed medical journal read by over 25,000 oncologists and cancer care professionals nationwide. This indexed publication delivers the latest insights into best clinical practices, oncology health services research, and translational medicine. Notably, JNCCN provides updates on the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), review articles elaborating on guideline recommendations, health services research, and case reports that spotlight molecular insights in patient care.
Guided by its vision, JNCCN seeks to advance the mission of NCCN by serving as the primary resource for information on NCCN Guidelines®, innovation in translational medicine, and scientific studies related to oncology health services research. This encompasses quality care and value, bioethics, comparative and cost effectiveness, public policy, and interventional research on supportive care and survivorship.
JNCCN boasts indexing by prominent databases such as MEDLINE/PubMed, Chemical Abstracts, Embase, EmCare, and Scopus, reinforcing its standing as a reputable source for comprehensive information in the field of oncology.